Publications
2011
Al-Dakkak, I., Patel, S., Jen, MH., von Maltzahn, R. R… You aware how useful it is? The value of correlation coefficients in meta-analysis. Poster presentation PRM46: 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2011. PRM46.
Alnwick, K. AHRQ versus NICE: Do the conclusions in CER reports correspond closely to the comparative effectiveness assessments made in HTA reports? Poster presentation PHP84: 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2011. PHP84.
Cost, P. The case of rare disease drugsin the context of pricing bodies: lessons from Brazil, Canada, and the UK, implications for the US. Poster presentation PHP108: 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2011. PHP108.
Green, MJ. IQWIG and HIGQ, what are they good for? The evolution of the HTA agency: Time from creation to first assessment and impactful apprasial. Poster presentation PHP 113: 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2011. ISPOR.
Grundstrom, JP. Mini-HTA trends for medical devices in the Nordics. Poster presentation PMD39: 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2011. PMD39.
Gupta, J., Siddiqui, MK, Jindal, R., Sehgal, M. Safety profile of latanoprost versus timololin in patients with open angle glaucoma or ocular hypertension: Post 2000 setting. Poster presentation PSS6: 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2011. PSS6.
Haulon S, Khodja RH, Proudfoot CW, Samuels E. (2011) A Systematic Literature Review of the Efficacy and Safety of the Prostar XL Device for the Closure of Large Femoral Arterial Access Sites in Patients Undergoing Percutaneous Endovascular Aortic Procedures. European Journal Vascular Endovascular Surgery 41(2): 201-213. PubMed.
Kumar, J., Bachman, EM. Pricing and reimbursement of orphan drugs in Canada. Poster Presentation PHP100: 16th Annual International meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2011. PHP100.
Lion, M., Murphy, D., Hettle, R. Pietri, G., Lock, L., Moorcroft, E. Evaluation of consistency between multiple sclerosis registry publications. Poster presentation PND 61: 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2011. ISPOR.
Rana, C., Mann, K., Wadhwa, A. Assessment of safety profile of trastuzumab in metastatic breast cancer patients. Poster presentation PCN22: 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2011. ISPOR.
Ross, S., Samuels, E., Gairy, K., Iqbal, S., Badamgarav, E., Siris, E. A Meta-Analysis of Osteoporotic Fracture Risk with Medicaion Nonadherence. Value in Health 14 (2011): 571-581. PubMed.
Siddigui, MK, Gupta, J., Bhutani, M., Sehgal, M. Opiods in non-malignant pain: are they equivalent in safety profile? A network meta-analysis. Poster presentation PSY3: 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2011. PSY3.
Sweet, A., Lee, D., Gairy, K., Phiri, D., Reason, T., Lock, K. (2011). The Impact of CT Colonography for Colorectal Cancer Screening on the UK NHS: Costs, Healthcare Resources, and Health Outcomes. Applied Health Economics & Policy 9(1):51-64. PubMed.
Ternouth, AM, Jakel, A., Plested, M., Modha, R. HTA decision drivers for acceptance of high ICER submissions and rejection of low ICER submissions. Poster presentation PHP 83: 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2011. PHP83.
Wu, Y., Modha, R., Seghal, M., Dhawan, R. Unmet need in metastatic prostate cancer patients: results from a systematic review. Poster presentation PCN14: 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2011. ISPOR.
Xia, AD. Comparative effectiveness reviews and their potential impact on formulary access in the United States. Poster presentation PHP 103: 16th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2011. ISPOR.
2010
Aggarwal A. Emergency contraception for unintended pregnancy: Role of Ulipristal, a novel progesterone receptor modulator. Poster presentation PIH1: 13th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, 2010. PIH1.
Alnwick K, Fisher M. Review of pharmacoeconomic recommendations for the definition of societal perspective. Poster presentation PMC2: 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2010. PMC2.
Balvanyos J, Alnwick K, Proudfoot C. Clinical evidence requirements: comparison between HTA agencies and implications for drug manufacturers. Poster presentation PHP107: 13th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, 2010. PHP107.
Balvanyos J, Alnwick K, Proudfoot C. Economic evidence requirements: comparison between seven HTA agencies and implications for drug manufacturers. Poster presentation PHP108: 13th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, 2010. PHP108.
Fisher M, Waycaster C, Vanoli A, Muston D. Cost-effectiveness analysis of the acrysof Cachet phakic intraocular Lens. Poster Presentation PSS4: 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2010. PSS4.
Freemantle N, Mason M, Mosquesda JG, Nixon F, Budhia, S. Efficacy of second line treatments in patients with metastatic hormone refractory prostate cancer (mhrpc) is not demonstrated by published evidence from non-randomised trials. Poster presentation PCN12: 13th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, 2010. PCN12.
Jakel A, Alnwick K. Evaluation of reasons for rejection of orphan drugs across six HTA agencies. Poster presentation PHP100: 13th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, 2010.
Knight C, Howard P, Baker CL, Marton JP. (2010) The cost-effectiveness of an extended course (12 + 12 weeks) of varenicline compared with other available smoking cessation strategies in the United States: an extension and update to the BENESCO model. Value in Health, 13(2):209-214. PubMed.
Lee D, Muston D, Sweet A, Cunningham C, Slater A, Lock K. (2010) Cost effectiveness of CT colonography for UK NHS colorectal cancer screening of asymptomatic adults aged 60–69 years. Applied Health Economics and Health Policy, 8 (3): 141-154. PubMed.
Mann K, Rana C, Wadhwa A. Preserved antitumor activity and reduced cardio-toxicity of first-line pegylated liposomal doxorubicin compared with conventional doxorubicin in patients with metastatic breast cancer. Poster presentation PCN6: 13th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, 2010. PCN6.
Modha R, Wieffer H, Pietri G, Pueschner F, Gaudig M. Establishing the comparative efficacy of Alzheimer’s disease therapy through systematic review and comparative analysis. Poster presentation PMH5: 13th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, 2010. PMH5.
Oraro T, Alnwick K. Evaluation of acceptance and rejection rates of orphan drugs across six HTA bodies. Poster presentation PHP101: 13th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, 2010. PHP101.
Plested M, Budhia S, Gabrieal Z. (2010). Pregabalin, the lidocaine plaster and duloxetine in patients with refractory neuropathic pain: a systematic review. BMC Neurology. 10:116. PubMed.
Scrutton HC, Samuels ER. What is the current R&D landscape for metastatic breast cancer? An investigation into recent clinical trial activity. Poster presentation PCN142: 13th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, 2010. ISPOR.
Sedelnikova S, Modha R, Lock K, Howard P. Surrogate outcomes in HTA decision making. Oral presentation (R Modha) CAPT Annual Conference, Toronto, March 28-30, 2010.
Sedelnikova S, Modha R, Lock K, Howard P. Surrogate outcomes in HTA decision making. Poster presentation, CADTH symposium, Halifax, Nova Scotia, April 18-20, 2010. CADTH.
Sharma R, Arora M, Ubhadiya B. Impact of placebo run-in period on relative treatment effect in Generalized Anxiety Disorder (GAD). Poster presentation PMH73: 13th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, 2010. PMH73.
Siddiqui MK, Gupta J, Sehgal M. Health related quality of life (HRQoL) in cervical carcinoma: Clinical significance and methodological issues. Poster presentation PCN131: 13th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, 2010. PCN131.
Srivastava K, Sharma S, Ahuja A, Taneja A. Cost of illness associated with renal transplantation and dialysis in end stage renal disease in the United States. Poster presentation PUK16: 13th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, 2010. PUK16.
Ternouth A, Chapman M, Modha R. An assessment of the variation in accepted ICERs by disease type: results from four HTAs. Poster presentation PHP66: 13th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, 2010. PHP66.
Trevor NC, Alnwick K. How can the use of predictive biomarkers lead to positive HTA recommendations? Poster presentation PHP105: 13th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, 2010. PHP105.
Trevor NC, Tang M, Samuels ER. Investigating the impact of R&D investment and policy innovative performance in Europe. Poster presentation PHP55: 13th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, 2010. PHP55.
Xia A, Oraro T. First-in-therapy products and requirements for successful HTA assessment. Poster presentation PHP99: 13th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, 2010. PHP99.
Zhang Y. Inclusion of conference abstract data in systematic reviews of pharmacologic interventions in different disease areas. Poster presentation PMC60: 13th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research, 2010. PMC60.
Zhang Y, Wieffer H, Modha R, Balar B, Pollack M, Krishnarajah G. Impact of hypoglycaemia on patient reported outcomes: A systematic literature review. Poster presentation PDB53: 15th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2010. ISPOR.
2009
Aggarwal A. Burden and cost of snakebite envenoming: Antivenom out of reach? Poster presentation PIN21: 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2009
Agrawal R, Dimri S, Ubhadiya BS, Narvilkar P, Bhanderi M. Reporting quality of double-blind randomized controlled trials and its association with the funding agency. Poster presentation PMC91: 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2009
Arora A, Aneja G, Shukla H, Alnwick K. Type 2 diabetes – influence of lifestyle change? Poster presentation PIN32: 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2009
Bhanderi M, Dimri S, Mahajan A, Ubhadiya BS, Narvilkar P, Agrawal R, Singh N. The nature and scale of inadequate reporting of dichotomous outcomes from six systematic reviews. Poster presentation PMC7: 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2009
Chapple CR, Khullar V, Gabriel Z, Muston D, Bitoun C, Weinstein D, Kopp Z. ‘Diagnosis and treatment of overactive bladder’ in `Evidence-based urology’. Editors: Philipp Dahm and Roger Dmochowski. Publishers: Blackwell, Oxford, 2010 (submitted 2009)
Dimri S, Ubhadiya BS, Singh N, Narvilkar P, Bhanderi M. An exploratory analysis of reasons behind premature termination of randomized controlled trials. Poster presentation PMC88: 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2009
Fisher M, Muston D, Knight C. Review and chronology of smoking cessation models. Poster presentation PMC46: 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2009
Gairy K, Lee D, Muston D. Economic analysis of CT colonography screening for colorectal cancer. Oral presentation, GASTRO 2009
Glassup F, Modha R, Muston D, Kerrigan J, Misra A, Williams R. Use of indirect comparison in HTA submissions. Poster presentation PHP82: 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2009
Goyal R, Rai MK, Chawla A, Siddiqui MK, Srivastava K. Pharmacogenomics: Applicability in Antiretro Viral Therapy (ART) in HIV Patients. Poster presentation PIN5: 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2009
Imrie J, Galani C, Gairy K, Lock K, Hunsche E. (2009) Cost of illness associated with Niemann-Pick disease type C in the UK. Journal of Medical Economics, 12(3): 219-229
Jackson DL, Proudfoot CW, Cann KF, Walsh TS. (2009) The incidence of sub-optimal sedation in the ICU: a systematic review. Critical Care, 13(6):R204.
Karia, R., Plested, M. (2009) Health Technology Assessments: Trend in Decision-Making. ISPOR Connections: Uniting Science and Practice. https://www.ispor.org/news/articles/November09/htatdm.asp.
Karia R, Plested, M. The impact of the submission sequence – which appraising body to submit to first? Poster presentation PHP87: 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2009
Karia R, Zwaferink H, Malik M. Relevance of conference abstracts and hand-searching in systematic reviews. Poster presentation PMC32: 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2009
Lenox-Smith A, Greenstreet L, Burslem K, Knight C. (2009) Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major depressive disorder in the UK. Clinical Drug Investigation, 29(3): 173-184
Muston D, Downs T, Rives V. (2009) An economic evaluation of topical treatments for actinic keratosis. Journal of Dermatological Treatment, 20(5):266-75
Nixon F, Chan M. A comparison of policies on paediatric dosing guidelines and indications between the United States and Europe. Poster presentation PHP8: 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2009
Parker SG, Oliver P, Pennington M, Bond J, Jagger C, Enderby PM, Curless R, Chater T, Vanoli A, et al. (2009) Rehabilitation of older patients: day hospital compared to rehabilitation at home. A randomised controlled trial. Health Technology Assessment, 13(39): 1-143
Pietri G, Muston D. Systematic review reliability: efficacy of two independent reviewers and two step reviews. Poster presentation PMC8: 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2009
Plested M, Karia R, Samuels E. A comparison of reasons for recommendation and rejection across four health technology appraisal systems categorised by disease. Poster presentation PHP84: 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2009
Rai MK, Goyal R, Srivastava K, Siddiqui MK, Chawla A, Joshi B, Sehgal M. Pharmacoeconomic Relevance of Antiretro Viral Therapy (ART) in Low and Middle Income Countries. Poster presentation PIN32: 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2009
Samuels E, Phiri D. Where is the current focus of health economics? An investigation into the published literature within three key health economics journals. Poster presentation PMC23: 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2009
Sarkany M, Downs T, Muston D, Rives V. Photodynamic therapy with methyl aminolevulinate (MAL-PDT) is less expensive and more effective than imiquimod in the management of actinic keratosis in the United Kingdom. Poster presentation P861: 18th Congress of the European Academy of Dermatology and Venereology, October 2009
Sedelnikova S, Lock K, Modha R. The use of surrogate outcomes in HTA decision making and recommendations. Oral presentation (R Modha) DIA HTA Forum, Nov. 25–26, 2009
Singh N, Dimri S, Mahajan A, Agrawal R, Ubhadiya BS, Narvilkar P, Bhanderi M. The nature and scale of inadequate reporting of continuous outcomes from four systematic reviews. Poster presentation PMC6: 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2009
Soini EJO, Martikainen JA, Vanoli A. Cost-effectiveness and budget impact modelling (BIM) of lacosamide in the treatment of partial-onset seizures (POS) in Finland. Poster presentation PND9: 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2009
Srivastava K, Rai MK, Siddiqui MK, Goyal R, Chawla A, Takyar S, Sharma S. Incidence rate and burden of illness of cervical cancer in United States of America. Poster presentation PCN59: 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2009
Sweet A, Muston D, Lock K, Lee D. Colorectal cancer screening: cost-effectiveness of CT colonography. Poster presentation PCN96: 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2009
Tsertsvadze A, Stoddart S, Plested M. Updating Systematic Reviews – their importance and techniques for updating. Workshop presented at 14th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2009
2008
Arora M, Srivastava K, Siddiqui MK, Verma J, Ahuja M, Sharma S. (2008) Socio-economic impact of avian influenza in South-East Asia and neighbouring high risk countries. Poster presentation PIN36: 11th Annual European Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008
Bhanderi M, Singh N, Kumar R, Chawla A, Sehgal M. (2008) Quality of life measurement in current clinical trials: focus on chronic diseases. Poster presentation PMC5: 3rd annual Asia-Pacific meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008
Cann K, Karia R, Plested M, Samuels E. (2008) A comparison of reasons for recommendation and rejection in four health technology appraisal systems: NICE, SMC, CADTH and PBAC. Podium presentation HT3: 11th Annual European Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008
Chapple C, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D, Kopp Z. (2008) The Effects of Antimuscarinic Treatments in Overactive Bladder:An Update of a Systematic Review and Meta-Analysis. European Urology, 54(3) 543-62
Chapple C, Khullar V, Gabriel Z, Muston D, Bitoun CE, Weinstein D. (2008) The safety and tolerability of antimuscarinic treatments in overactive bladder: results from an update of a systematic review and meta-analysis. Presentation 69 – 33rd annual meeting of the International Urogynecological Association
Chawla A, Kumar R, Aneja G, Bhanderi M, Seghal M. (2008) Pharmacogenomics: relevance and applicability in post-genomic era (HIV-therapy). Poster presentation PIN7: 11th Annual European Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008.
Denton CP, Nihtyanova S, Hunsche E, Gani R. (2008) Economic implications of severe digital ulcer disease – a cost of illness analysis of patients receiving specialized care in the UK. Annals of the Rheumatic Diseases, 67(Suppl II) 431
Gani R, Giovannoni G, Bates D, Kemball B, Hughes S, et al. (2008) Cost-effectiveness analysis of natalizumab compared with other disease modifying treatments for people with highly active relapsing-remitting multiple sclerosis in the UK. Pharmacoeconomics, 26(7) 617-27
Gani R, Samuels ER, Hughes S, Giovanonni G. (2008) A cost effectiveness analysis of natalizumab vs. interferon-beta and glatiramer acetate in patients with active relapsing-remitting multiple sclerosis currently failing on existing therapy. Poster presentation PND13: 13th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008
Howard P, Knight C, Boler A, Baker C. (2008) Cost-utility analysis of varenicline versus existing smoking cessation strategies using the BENESCO simulation model – application to a population of US adult smokers. Pharmacoeconomics, 26(6) 497-511
Jackson D, Proudfoot CW, Knight CJ, Cann K, Lock K. (2008) Inappropriate sedation in ICUs: evidence from the literature. Poster presentation PHP57: 11th Annual European Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008
Jackson D, Proudfoot CW, Knight CJ, Cann K, Lock K. (2008) Impact of ICU sedation practice on patient morbidity, cost and hospital resource use: a systematic review. Poster presentation PHP56: 11th Annual European Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008
Karia R, Plested M, Cann K, Zwaferink H. (2008) Update of results and outcomes of NICE single technology appraisals – economic criticisms, Podium presentation HT2: 11th Annual European Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008
Karia R, Gani R, Perard R and Cann K. (2008) A comparison of three technology appraisal systems: NICE, SMC and CADTH. Podium presentation HP1: 13th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008
Khullar V, Chapple C, Gabriel Z, Muston D, Bitoun CE, Weinstein D. (2008) The patient-perceived effects of antimuscarinic treatment: results from an update of a systematic review and meta-analysis. Presentation 70 – 33rd annual meeting of the International Urogynecological Association
Lee CW, Buckley F, Costello S, Kelly S. (2008) A systematic review of the characteristics of randomised control trials featuring prostaglandins for the treatment of glaucoma. Current Medical Research & Opinion, 24(8) 2265-70
Lee CW, Buckley F, Costello S, Stoddart SD, Kelly S. (2008) The RCT evidence of comparative effectiveness and safety of topical glaucoma medication. Poster presentation PSS4: 13th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008
Lee CW, Stoddart SD, Muston D, Buckley F, Costello S, Kelly S. (2008) Systematic review and meta-analysis of RCTs regarding the comparative incidence of hyperaemia of prostaglandin topical glaucoma medications. Poster presentation PSS24: 11th Annual European Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008
Lock K, Samuels E. (2008) Trends in research into central nervous system disorders: the influence of an aging population. Poster presentation PND28: 11th Annual European Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008
Muston D. (2008) Cost-effectiveness sensitivity to cost-effectiveness correlation: a simulation study. Poster presentation PMC21: 13th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008
Muston D, Alnwick K. (2008) Systematic review reliability: sensitivity and specificity of one vs. two reviews. Poster presentation PMC63: 11th Annual European Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008
Muston D, Perard R, Nixon F. (2008) Characteristics of risk-sharing schemes in Europe. Poster presentation PHP68: 13th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008
Narvilkar P, Mahajan A, Dimri S, Kumar R, Seghal M. (2008) Role of disease specific instruments in the measurement of Health-Related Quality of Life in cancer clinical trials. Podium presentation QL6: 11th Annual European Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008
Nixon F. (2008) The reimbursement of orphan drugs across Europe. Poster presentation PHP45: 11th Annual European Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008
Proudfoot CW, Alnwick K. (2008) What proportion of diseases are QALYS an irrelevant measure for? Poster presentation PMC45: 11th Annual European Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008
Proudfoot C, Plested M, Buckley F. (2008) Search strategies and results of systematic reviews. Poster presentation PMC1: 13th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008
Proudfoot CW, Stoddart SD, Muston D. (2008) Has the quality of randomized controlled trials increased with time: an analysis of data from 5 systematic reviews. Poster presentation PMC2: 11th Annual European Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008
Samuels E, Lock K, Karia R, Stoddart SD. (2008) Prevalence of research focuses on genetically-linked disorders: where have we been and where are we going? Poster presentation PMC53: 13th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008
Samuels E, Plested M. (2008) Categorising research: where is the focus? Poster presentation PHP46: 11th Annual European Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008
Samuels E, Stoddart SD, Lock K, Karia R. (2008) Huntington’s disease: where have we been? Poster presentation PND2: 11th Annual European Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008
Ubhadiya BS, Gautum C, Narvilkar P, Singh N, Bhanderi M, Dimri S. (2008) Design and reporting trends in piggy-back economic trials. Poster presentation PMC8: 11th Annual European Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2008
2007
Buckley F, Proudfoot C, Boler A. (2007) Evaluating the effectiveness of search strategies for systematic review. Value In Health, 10(6) A459
Gani R, Nixon R, Hughes S, Jackson C. (2007) Estimating the rates of disability progression in people with relapsing-remitting multiple sclerosis. Journal of Medical Economics, 10, 79-89.
Gani R, Ravndal F. (2007) Assessing levels of association between health-care expenditure and health-care indicators in economically developed countries. Value In Health, 10(3) A30
Hughes D, Sridhar F, Elliot R, Cowell W, Budhia S. Interventions that enhance medication compliance and persistence: theoretical grounding, and economic assessment. 10th annual European congress of the International Society for Pharmacoeconomics and Outcomes Research, 20-13 October 2007, Dublin, Ireland
Karia R, Gani R, Boler A. (2007) Results and outcomes of NICE single technology appraisal process. Value in Health, 10(6) A370-A371
Knight C, Howard P, Baker C. (2007) An evaluation of the cost-effectiveness of an extended course of varenicline in preventing smokers who have quit from relapsing. Value in Health, 10(6) A472
Knight C, Howard P, Baker C. (2007) Estimating the incidence and prevalence of smoking related morbidities using proxy values. Value In Health, 10(3) A101
Muston D. (2007) Examining incentives for subgrouping in NICE submissions. Value in Health, 10(6) A371
Muston D, Boler A. A practical guide to indirect/mixed treatment comparisons. 12th Annual International Meeting of the International Society for Pharmacoeconomics and Outcomes Research, 2005
Muston D, Howard P. (2007) Price vs. access: a probabilistic model for guiding pricing decisions. Value In Health, 10(3) A187
Orme M, Kerrigan J, Tyas D, Russel N, Nixon R. (2007) The effect of disease, functional status, and relapses on the utility of people with multiple sclerosis in the UK. Value In Health, 10(1): 54-60
Perard R, Gani R. European pricing and reimbursement update: optimal monetary benefits can depend on which country the process is initiated. Value in Health, 10(6) A370
Tyas N, Kerrigan J, Russel N, Nixon R. (2007) The distribution of the cost of multiple sclerosis in the UK: how do costs vary by illness severity? Value In Health, 10(5): 386-389
2006
Gani R, Hughes S, Jackson C, Nixon R. Disability progression rates in people with active relapsing-remitting multiple sclerosis. ECTRIMS 2006, 22nd congress of the European committee for treatment and research in multiple sclerosis, September 27-30 2006, Madrid, Spain
Howard P, Muston D. (2006) Bowel cancer screening. Balancing cost-effectiveness and affordability. Value In Health, 9(6), A291
Khullar V, Chapple C, Gabriel Z, Dooley JA. (2006) The effects of antimuscarinics on health-related quality of life in overactive bladder: a systematic review and meta-analysis. Urology, 68(2 Suppl): 38-48.
Knight C. (2006) A care map for CHF in the UK. Value In Health, 9(6), A355
Muston D, Howard P, Lee D. (2006) A model for projecting bowel cancer incidence and mortality: application to the UK bowel cancer screening program. Value In Health, 9(6), A290
Orme M, Boler A. (2006) Prostaglandin analogues for the treatment of glaucoma and ocular hypertension: a systematic review of economic evidence. Pharmacoeconomics, 24(8): 743-750
2005
Boler A, Lister S. (2005) Body mass index (BMI) and trends in GP consultations and prescribing: A UK NHS perspective. Value In Health, 8(3), 255
Chapple C, Khullar V, Gabriel Z, Dooley J. (2005) The effects of antimuscarinic treatments in overactive bladder: a systematic review and meta analysis. European Urology, 48, 5-26.
Chapple C, Khullar V, Gabriel Z, Dooley J. Comparative safety and tolerability of antimuscarinic treatments for overactive bladder. XXth EAU congress, 16-19 March 2005, Istanbul, Turkey
Gabriel Z, Khullar V, Chapple C, Dooley J. ‘Lumping’ versus ‘Splitting’: a comparison of two systematic reviews of antimuscarinic treatment for overactive bladder. 30th Meeting of the International Urogynecological Association, 9-12 August 2005, Copenhagen, Denmark
Khullar V, Chapple C, Gabriel Z, Dooley J. Duloxetine compared with antimuscarinics for the treatment of mixed urinary incontinence: an assessment of adverse events and withdrawals. 30th meeting of the International Urogynecological Association, 9-12 August 2005, Copenhagen, Denmark
Khullar V, Chapple C, Gabriel Z, Dooley J. Quality of life measurement in trials of antimuscarinic therapies for overactive bladder. XXth EAU Congress, 16-19 March 2005, Istanbul, Turkey
Richard L, Lister S. (2005) A preliminary analysis of the relationship between consultation length and prescriber activity in UK general practice. Value In Health, 8(3), 295
Richard L, Lister S. (2005) An exploration of patient factors in influencing prescriber activity in UK general practice. Value In Health, 8(3), 295
Richard L, Odeyemi I, Ward A. (2005) A review of the economic evidence for botulinum toxins in spasticity associated with stroke and cerebal palsy. Value In Health, 8(6), A131
Richard L, Odeyemi I, Ward A. The need for consensus in outcome measures for assessment of interventions for spasticity. European Neurological Society, 15th Meeting, 18-22nd June 2005, Vienna, Austria
2004
Boler A, Howard P. (2004) A systematic review of the effectiveness of total and partial laparoscopic fundoplication for the treatment of GORD. Value In Health, 7(3), 346-347.
Gabriel Z, Richard L. (2004) Blood donation in the 21st century: motivation amidst crisis. Value In Health, 7(3), 316-317
Gosden T, Costello S, Orme M, Howard P, Dooley J. (2004) Cost effectiveness of latanoprost in first line treatment of primary open angle glaucoma in the UK. Value In Health, 7(6), 747
Howard P, Knight C. (2004) A clinical and cost effectiveness comparison of venlafaxine and selective serotonin reuptake inhibitors (SSRIS) in the management of patients with major depressive disorder from the perspective of an Austrian sickness fund. Journal of Medical Economics, 7, 93-106
Lenox-Smith A, Conway P, Knight C. (2004) Cost effectiveness of representatives of three classes of antidepressants used in major depression in the UK. Pharmacoeconomics, 22(5): 311-319
Orme M, Howard P. (2004) The cost-effectiveness of methyl aminolevulinate photodynamic therapy (MAL-PDT) for difficult to treat actinic keratoses. Value In Health, 7(3), 260-261
Orme M, Howard P. (2004) The cost-effectiveness of methyl aminolevulinate photodynamic therapy (MAL-PDT) for basal cell carcinoma. Value In Health, 7(3), 248-249
Orme M, Daniels S. (2004) Calculating the cost of wound care in a community setting in the UK: an example using modern wound management dressings. Value In Health, 7(6), 762
2003
Boler A, Wenk-Lang A, Howard P. (2003) A cost consequence analysis of new endoscopic, injectable treatment and existing interventions in gastro-oesophageal reflux disease. Value In Health, 6(6), 613
Boler A, Howard P. (2003) The implications of combining heterogeneous patient populations in meta-analyses. Value In Health, 6(6), 610-611
Bosanquet N, Domeninghetti G, Beresniak A, Auray J, Crivelli L, et al. (2003) Equity, access and economic evaluation in rare diseases. Pharm Dev Regul., 1(3): 151-157
Conway P, Knight C. (2003) First and second year UK treatment costs associated with the use of anti-TNF drugs in patients with rheumatoid arthritis. Rheumatology, 46(Suppl 1), 87
Orme ME, Jurewicz WA, Kumar N, McKechnie TL. (2003) The cost effectiveness of tacrolimus versus microemulsified cyclosporin: a 10-year model of renal transplantation outcomes. Pharmacoeconomics, 21(17): 1263-1276
Richard L. (2003) A review of the pharmacotherapeutic management of pulmonary arterial hypertension. Value In Health, 6(3), 6
Richard L. (2003) Pharmacoepidemiology: a review of its emerging role in outcomes research. Value In Health, 6(3), 295
Wenk-Lang A, Knight C. (2003) Cost-effectiveness analyses of TAXUS(TM) drug-eluting stent in the UK. Value In Health, 6(6), 661
2002
Boler A. (2002) Trends in data sources used for economic evaluation. Value In Health, 5(6), 531-532.
Duru G, Auray JP, Beresniak A, Lamure M, Paine A, et al. (2002) Limitations of the methods used for calculating quality-adjusted life-year values. Pharmacoeconomics, 20(7): 463-473.
Ready A, Yi-Hua C, Barratt R, Sen S, Knight C, et al. (2002) Funding decisions for anti-rejection therapies; the use of real costs and economic models to predict cost-effectiveness. British Transplantation Society
Richard L, Howard P, Thorpe T. (2002) A review of the pharmacotherapeutic management of pulmonary arterial hypertension. Value In Health, 5(6), 492-493.
Richard L. (2002) The relationship between disease area and type of economic study – does it exist. Value In Health, 5(3), 212
2001
Daniels S, Kerrigan J. (2001) Modern wound dressings are more cost-effective than traditional gauze dressings in managing difficult to heal surgical wounds. European Wound Management Association 2001, Dublin, Ireland.
Kerrigan J, Knight C. (2001) Do health care purchasers prefer paying for life extension of quality of life improvement? Value In Health, 4(6), 423-424.
Ready A, Yi-Hua C, Barratt R, Sen S, Knight C. (2001) Funding restrictions for new anti-rejection therapies in the UK. Modelling for cost-effectiveness may provide a means of challenge. Renal Association autumn meeting, 20-21 September 2001, The Royal College of Physicians, London, UK
2000
Hakim Z, Howard P, Farina C. (2000) Estimating health state preferences in obesity. ISOQOL 2000
Knight C, Ratcliffe A, Howard P, Farina C. (2000) Modelling of anti-obesity treatment: cost-effectiveness model in the UK. Value In Health, 3(5), 361
1999
Ilersich L, Howard P. (1999) Pharmacoeconomic analysis of clodronate and pamidronate in osteolytic bone disease in Canada and the UK. Canadian Health Technology Assessment
Kerrigan J, Humphrey K, Duscheiko G, Foster G, Rosenberg W. (1999) A novel approach to markov modelling: a computer forecasting tool to model the costs and consequences of the management of the hepatitis C virus (HCV). International Journal of Technology Assessment in Health Care, 15, 499
Sweetenham J, Hieke K, Kerrigan M, Howard P, Smarrt P. (1999) Cost minimisation analysis of CHOP, fludarabine and rituximab for the treatment of relapsed, indolent B-cell non hodgkin’s lymphoma in the UK. British Journal of Haematology, 106, 47-54
1998
Howard P, Hieke K, Kerrigan M, Smarrt P, McIntyre A, et al. (1998) Cost minimisation analysis of CHOP, fludarabine and rituximab for the treatment of relapsed indolent B-cell non-hodgkin’s lymphoma in the UK. Satellite symposium of British Society of Haematology
Sweetenham J, McIntyre A, Howard P, Smarrt P, Kerrigan M, et al. (1998) Comparative economic analysis of the treatment of relapsed low-grade B-cell non hodgkin’s lymphoma (NHL) using CHOP, fludarabine or rituximab. American Society of Hematology, annual meetin